Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Associate

Adi E. Vinyarsh

Goodwin Procter

main

Vinyarsh Adi

Goodwin Associate Adi Vinyarsh, from New York, practices in the Business Law Department. Learn more about Adi's experience, recent cases & contact details.

Adi E. Vinyarsh

Areas of Practice

Professional Experience

Credentials

Education

Master of Laws2017

Master of Laws2017

Bachelor of Laws2015

Admissions

Bars

Recognition & Awards

Related Content

Cann Completes $27 Million Series A

Capital Markets and Women’s Health and Wellness Teams Advise Underwriters in Femasys' $34.45 Million IPO

Goodwin Israel Practice Advises on Over $400 Million in Multiple Financings, a $28 Million Public Offering, and a De-SPAC

Capital Markets Team Advises Underwriters Of Laird Superfood’s $67 Million Initial Public Offering

iTeos Therapeutics Closes Upsized $201.1 Million Initial Public Offering

Capital Markets Team Advises Underwriters of $85.1 Million RenalytixAI Global Offering

iTeos Therapeutics Completes Series B2 Financing Round Raising $125 Million

Monotype to Be Acquired by HGGC for an Aggregate Equity Value of Approximately $825 Million

Cannabis

Life Sciences

Technology

Fintech

Technology M&A

New Company Formation

Venture Capital